Top

Published in:

Open Access 01-04-2022 | Prostate Cancer | Invited Review

Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis

Authors: Reza Sari Motlagh, Mohammad Abufaraj, Pierre I. Karakiewicz, Pawel Rajwa, Keiichiro Mori, Dong-Ho Mun, Shahrokh F. Shariat

Published in: World Journal of Urology | Issue 4/2022

Abstract

Purpose

Androgen-regulated enzymes such as the angiotensin-converting enzyme 2 (ACE2) and the transmembrane serine protease 2 (TMPRSS2) are involved in the SARS-CoV-2 infection process. The expression of TMPRSS2 and its fusion gene, which are increased in the epithelium of the human prostate gland during prostate carcinogenesis, are regulated by androgens. Our goal was to assess the risk of the SARS-CoV-2 infection and the severity of the disease in PCa patients treated with androgen deprivation therapy (ADT).

Methods

We conducted a systematic review and meta-analysis according to PRISMA guidelines. We queried PubMed and Web of Science databases on 1 July 2021. We used random- and/or fixed-effects meta-analytic models in the presence or absence of heterogeneity according to Cochrane’s Q test and I² statistic, respectively.

Results

Six retrospective studies (n = 50,220 patients) were selected after considering inclusion and exclusion criteria for qualitative evidence synthesis. Four retrospective studies were included to assess the SARS-CoV-2 infection risk in PCa patients under ADT vs. no ADT and the summarized risk ratio (RR) was 0.8 (95% confidence intervals (CI) 0.44–1.47). Five retrospective studies were included to assess the severity of coronavirus disease 2019 (COVID-19) in PCa patients under ADT versus no ADT and the summarized RR was 1.23 (95% CI 0.9–1.68).

Conclusion

We found a non-significant association between the risk of SARS-CoV-2 infection and COVID-19 severity in PCa patients treated with ADT. However, our results suggest that during the COVID-19 pandemic PCa patients can safely undergo ADT as a cancer therapy without worsening COVID-19 risk and trajectory.

O’Hearn M, Liu J, Cudhea F et al (2021) Coronavirus Disease 2019 hospitalizations attributable to cardiometabolic conditions in the united states: a comparative risk assessment analysis. J Am Heart Assoc. https://doi.org/10.1161/JAHA.120.019259CrossRefPubMedPubMedCentral

Peckham H, de Gruijter NM, Raine C et al (2020) Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 11:6317. https://doi.org/10.1038/s41467-020-19741-6CrossRefPubMedPubMedCentral

Rajwa P, Przydacz M, Krajewski W et al (2020) Changing patterns of urologic emergency visits and admissions during the COVID-19 pandemic: a retrospective, multicenter, nationwide study. Arch Med Sci. https://doi.org/10.5114/aoms.2020.98364CrossRefPubMedPubMedCentral

Thunders M, Delahunt B (2020) Gene of the month: TMPRSS2 (transmembrane serine protease 2). J Clin Pathol 73:773–776. https://doi.org/10.1136/jclinpath-2020-206987CrossRefPubMed

Roshandel MR, Nateqi M, Lak R et al (2020) Diagnostic and methodological evaluation of studies on the urinary shedding of SARS-CoV-2, compared to stool and serum: a systematic review and meta-analysis. Cell Mol Biol 66:148–156. https://doi.org/10.14715/cmb/2020.66.6.26CrossRefPubMed

Compérat E, Wasinger G, Oszwald A et al (2020) The genetic complexity of prostate cancer. Genes 11:1396. https://doi.org/10.3390/genes11121396CrossRefPubMedPubMedCentral

Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8:497–511. https://doi.org/10.1038/nrc2402CrossRefPubMedPubMedCentral

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2021) A phase ii trial to promote recovery from COVID-19 with endocrine therapy. clinicaltrials.gov

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2021) COMBO trial: camostat with bicalutamide for COVID-19. clinicaltrials.gov

10.

Josefsson A (2020) A prospective, multicenter, randomized phase ii clinical trial of enzalutamide treatment to decrease the morbidity in patients with corona virus disease 2019 (COVID-19). clinicaltrials.gov

11.

Corpometria Institute (2021) Early antiandrogen treatment (EAT) with dutasteride for COVID-19 (EAT-DUTA AndroCoV Trial). clinicaltrials.gov

12.

Applied Biology, Inc. (2021) Anti-androgen treatment for COVID-19. clinicaltrials.gov

13.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557CrossRefPubMedPubMedCentral

14.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605. https://doi.org/10.1007/s10654-010-9491-zCrossRefPubMed

15.

Agency for Healthcare Research and Quality (AHRQ). https://www.ahrq.gov/. Accessed 1 Apr 2021

16.

Koskinen M, Carpen O, Honkanen V et al (2020) Androgen deprivation and SARS-CoV-2 in men with prostate cancer. Ann Oncol 31:1417. https://doi.org/10.1016/j.annonc.2020.06.015CrossRefPubMed

17.

Kwon DH, Vashisht R, Borno HT et al (2021) Androgen deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. Ann Oncol. https://doi.org/10.1016/j.annonc.2021.01.067CrossRefPubMed

18.

Patel VG, Zhong X, Liaw B et al (2020) Does androgen deprivation therapy protect against severe complications from COVID-19? Ann Oncol 31:1419–1420. https://doi.org/10.1016/j.annonc.2020.06.023CrossRefPubMed

19.

Klein EA, Li J, Milinovich A et al (2021) Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2. J Urol 205:441–443. https://doi.org/10.1097/JU.0000000000001338CrossRefPubMed

20.

Montopoli M, Zumerle S, Vettor R et al (2020) Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol Off J Eur Soc Med Oncol 31:1040–1045. https://doi.org/10.1016/j.annonc.2020.04.479CrossRef

21.

Patel VG, Zhong X, Shah NJ et al (2021) The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer. J Clin Oncol 39:41–41. https://doi.org/10.1200/JCO.2021.39.6_suppl.41CrossRef

22.

Caffo O, Gasparro D, Di Lorenzo G et al (1990) (2020) Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. Eur J Cancer Oxf Engl 140:140–146. https://doi.org/10.1016/j.ejca.2020.09.018CrossRef

23.

Sari Motlagh R, Quhal F, Mori K et al (2021) The risk of new onset dementia and/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol 205:60–67. https://doi.org/10.1097/JU.0000000000001341CrossRefPubMed

24.

Abufaraj M, Iwata T, Kimura S et al (2021) Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. Eur Urol 79:44–53. https://doi.org/10.1016/j.eururo.2020.06.002CrossRefPubMed

25.

Smith MR, Lee WC, Brandman J et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 23:7897–7903. https://doi.org/10.1200/JCO.2004.00.6908CrossRef

26.

O’Callaghan ME, Jay A, Kichenadasse G, Moretti KL (2020) Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19. Ann Oncol 31:1780–1782. https://doi.org/10.1016/j.annonc.2020.09.014CrossRefPubMed

27.

Semaan L, Mander N, Cher ML, Chinni SR (2019) TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model. BMC Cancer 19:972. https://doi.org/10.1186/s12885-019-6185-0CrossRefPubMedPubMedCentral

28.

Blee AM, He Y, Yang Y et al (2018) TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res 24:4551–4565. https://doi.org/10.1158/1078-0432.CCR-18-0653CrossRef

29.

Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A (2021) Early antiandrogen therapy with dutasteride reduces viral shedding, inflammatory responses, and time-to-remission in males with COVID-19: a randomized, double-blind, placebo-controlled interventional trial (EAT-DUTA AndroCoV Trial—Biochemical). Cureus. https://doi.org/10.7759/cureus.13047CrossRefPubMedPubMedCentral

30.

Goren A, Wambier CG, Herrera S et al (2021) Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol JEADV 35:e13–e15. https://doi.org/10.1111/jdv.16953CrossRefPubMed

31.

Lazzeri M, Duga S, Azzolini E et al (2021) Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy). Minerva Urol E Nefrol Ital J Urol Nephrol. https://doi.org/10.23736/S0393-2249.20.04081-3CrossRef

Title: Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis
Authors: Reza Sari Motlagh
Mohammad Abufaraj
Pierre I. Karakiewicz
Pawel Rajwa
Keiichiro Mori
Dong-Ho Mun
Shahrokh F. Shariat
Publication date: 01-04-2022
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
SARS-CoV-2
Prostate Cancer
COVID-19
Androgens
Published in: World Journal of Urology / Issue 4/2022
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-021-03810-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2022

Epidemiology and care pathway of vesicovaginal fistulas managed in France between 2010 and 2018

Uncovering the role of urinary microbiota in urological tumors: a systematic review of literature

Re: Shedding light on polypragmasy of pain after transurethral prostate surgery procedures: a systematic review and meta-analysis

Correction to: Immunotherapy in prostate cancer: new horizon of hurdles and hopes

A perioperative inter-disciplinary and inter-professional approach for major open urological surgeries is crucial to optimize patient-specific outcomes

Extraperitoneal laparoscopic simple prostatectomy with urethra preservation using urethral initiation as the entry point: a practical approach for the treatment of benign prostatic obstruction